66 related articles for article (PubMed ID: 1388597)
1. Studies about the oral bioavailability of mitonafide and 2HCl amonafide, two new cytotoxic molecules.
Torres Suárez AI; Camacho Sánchez MA
Farmaco; 1992 Apr; 47(4):497-508. PubMed ID: 1388597
[TBL] [Abstract][Full Text] [Related]
2. Qualitative and quantitative determination of two new antitumor agents from 1-8 naphthalimides in tablets. Validation of a high performance liquid chromatography method.
Camacho MA; Torres AI; Gil ME; Obregón MM; Ruz V
Arzneimittelforschung; 1994 May; 44(5):659-62. PubMed ID: 8024643
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic characterization of mitonafide in man.
Brode E; Poveda Velasco A; Díaz-Rubio E; Rosell Costa R; Benavides Fissure A
Methods Find Exp Clin Pharmacol; 1992 Mar; 14(2):131-40. PubMed ID: 1598025
[TBL] [Abstract][Full Text] [Related]
4. Phase I study of amonafide dosing based on acetylator phenotype.
Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Vogelzang NJ; Lane LB
Cancer Res; 1993 May; 53(10 Suppl):2304-8. PubMed ID: 8485716
[TBL] [Abstract][Full Text] [Related]
5. Bis-naphthalimides: a new class of antitumor agents.
Braña MF; Castellano JM; Morán M; Pérez de Vega MJ; Romerdahl CR; Qian XD; Bousquet P; Emling F; Schlick E; Keilhauer G
Anticancer Drug Des; 1993 Aug; 8(4):257-68. PubMed ID: 8240655
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase II-mediated DNA cleavage by amonafide and its structural analogs.
Hsiang YH; Jiang JB; Liu LF
Mol Pharmacol; 1989 Sep; 36(3):371-6. PubMed ID: 2550774
[TBL] [Abstract][Full Text] [Related]
7. Limited sampling models for amonafide (NSC 308847) pharmacokinetics.
Ratain MJ; Staubus AE; Schilsky RL; Malspeis L
Cancer Res; 1988 Jul; 48(14):4127-30. PubMed ID: 3383202
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and metabolism of the antitumor drug amonafide (NSC-308847) in humans.
Felder TB; McLean MA; Vestal ML; Lu K; Farquhar D; Legha SS; Shah R; Newman RA
Drug Metab Dispos; 1987; 15(6):773-8. PubMed ID: 2893701
[TBL] [Abstract][Full Text] [Related]
9. Correspondence re: Mark J. Ratain et al., Limited Sampling Models for Amonafide (NSC 308847) Pharmacokinetics.
Lemmer B
Cancer Res; 1989 Jun; 49(11):3139-40. PubMed ID: 2720672
[No Abstract] [Full Text] [Related]
10. Statistical method for evaluation of dissolution stability in the formulation development of solid dosage forms: tablets of amonafide.
Gil-Alegre ME; Bernabeu JA; Camacho MA; Torres-Suarez AI
Pharmazie; 2004 Jul; 59(7):541-7. PubMed ID: 15296092
[TBL] [Abstract][Full Text] [Related]
11. Photolability evaluation of the new cytostatic drug mitonafide.
Torres Suárez AI; Camacho MA
Arzneimittelforschung; 1994 Jan; 44(1):81-3. PubMed ID: 8135882
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical investigation of benzisoquinolinedione (amonafide) in adults with refractory or relapsed acute leukemia.
O'Brien S; Benvenuto JA; Estey E; Beran M; Felder TB; Keating M
Cancer Res; 1991 Feb; 51(3):935-8. PubMed ID: 1988134
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and biological evaluation of new mitonafide derivatives as potential antitumor drugs.
Antonini I; Volpini R; Dal Ben D; Lambertucci C; Cristalli G
Bioorg Med Chem; 2008 Sep; 16(18):8440-6. PubMed ID: 18774722
[TBL] [Abstract][Full Text] [Related]
14. Synthesis, structure and antitumor activity of new benz[d,e]isoquinoline-1,3-diones.
Braña MF; Castellano JM; Morán M; Emling F; Kluge M; Schlick E; Klebe G; Walker N
Arzneimittelforschung; 1995 Dec; 45(12):1311-8. PubMed ID: 8595091
[TBL] [Abstract][Full Text] [Related]
15. Paradoxical relationship between acetylator phenotype and amonafide toxicity.
Ratain MJ; Mick R; Berezin F; Janisch L; Schilsky RL; Williams SF; Smiddy J
Clin Pharmacol Ther; 1991 Nov; 50(5 Pt 1):573-9. PubMed ID: 1934870
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of Amonafide in dogs.
Lu K; McLean MA; Vestal ML; Newman RA
Cancer Chemother Pharmacol; 1988; 21(2):134-8. PubMed ID: 3349561
[TBL] [Abstract][Full Text] [Related]
17. Novel thiazonaphthalimides as efficient antitumor and DNA photocleaving agents: effects of intercalation, side chains, and substituent groups.
Li Z; Yang Q; Qian X
Bioorg Med Chem; 2005 Aug; 13(16):4864-70. PubMed ID: 15925513
[TBL] [Abstract][Full Text] [Related]
18. Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
Ratain MJ; Rosner G; Allen SL; Costanza M; Van Echo DA; Henderson IC; Schilsky RL
J Clin Oncol; 1995 Mar; 13(3):741-7. PubMed ID: 7884434
[TBL] [Abstract][Full Text] [Related]
19. Computer simulation of the binding of amonafide and azonafide to DNA.
Bear S; Remers WA
J Comput Aided Mol Des; 1996 Apr; 10(2):165-75. PubMed ID: 8741020
[TBL] [Abstract][Full Text] [Related]
20. Advanced colorectal adenocarcinoma: treatment with amonafide.
Marschke RF; Wieand HS; O'Connell MJ; Rubin J; Schutt AJ; Burch PA; Kovach JS
J Natl Cancer Inst; 1994 Jun; 86(12):944-5. PubMed ID: 8196086
[No Abstract] [Full Text] [Related]
[Next] [New Search]
